These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19051151)

  • 1. Is QSAR relevant to drug discovery?
    Doweyko AM
    IDrugs; 2008 Dec; 11(12):894-9. PubMed ID: 19051151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QSAR: dead or alive?
    Doweyko AM
    J Comput Aided Mol Des; 2008 Feb; 22(2):81-9. PubMed ID: 18189157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The advancement of multidimensional QSAR for novel drug discovery - where are we headed?
    Wang T; Yuan XS; Wu MB; Lin JP; Yang LR
    Expert Opin Drug Discov; 2017 Aug; 12(8):769-784. PubMed ID: 28562095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Novel Quantitative Structure-Activity Relationship Model to Accurately Predict Pulmonary Absorption and Replace Routine Use of the Isolated Perfused Respiring Rat Lung Model.
    Edwards CD; Luscombe C; Eddershaw P; Hessel EM
    Pharm Res; 2016 Nov; 33(11):2604-16. PubMed ID: 27401409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipophilicity in drug design: an overview of lipophilicity descriptors in 3D-QSAR studies.
    Ginex T; Vazquez J; Gilbert E; Herrero E; Luque FJ
    Future Med Chem; 2019 May; 11(10):1177-1193. PubMed ID: 30799643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational quantum chemistry and adaptive ligand modeling in mechanistic QSAR.
    De Benedetti PG; Fanelli F
    Drug Discov Today; 2010 Oct; 15(19-20):859-66. PubMed ID: 20709183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and validation of an in silico toxicology model to predict the mutagenic potential of drug impurities.
    Valerio LG; Cross KP
    Toxicol Appl Pharmacol; 2012 May; 260(3):209-21. PubMed ID: 22426359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive QSAR modeling for the successful predictions of the ADMET properties of candidate drug molecules.
    Khan MT; Sylte I
    Curr Drug Discov Technol; 2007 Oct; 4(3):141-9. PubMed ID: 17985997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology.
    Perkins R; Fang H; Tong W; Welsh WJ
    Environ Toxicol Chem; 2003 Aug; 22(8):1666-79. PubMed ID: 12924569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs.
    Chen M; Hong H; Fang H; Kelly R; Zhou G; Borlak J; Tong W
    Toxicol Sci; 2013 Nov; 136(1):242-9. PubMed ID: 23997115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative QSAR- and fragments distribution analysis of drugs, druglikes, metabolic substances, and antimicrobial compounds.
    Karakoc E; Sahinalp SC; Cherkasov A
    J Chem Inf Model; 2006; 46(5):2167-82. PubMed ID: 16995747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QSAR-based permeability model for drug-like compounds.
    Gozalbes R; Jacewicz M; Annand R; Tsaioun K; Pineda-Lucena A
    Bioorg Med Chem; 2011 Apr; 19(8):2615-24. PubMed ID: 21458999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based quantitative structure--activity relationship modeling of estrogen receptor β-ligands.
    Dong X; Hilliard SG; Zheng W
    Future Med Chem; 2011 Jun; 3(8):933-45. PubMed ID: 21707397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using kernel alignment to select features of molecular descriptors in a QSAR study.
    Wong WW; Burkowski FJ
    IEEE/ACM Trans Comput Biol Bioinform; 2011; 8(5):1373-84. PubMed ID: 21339534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrotopological state atom (E-state) index in drug design, QSAR, property prediction and toxicity assessment.
    Roy K; Mitra I
    Curr Comput Aided Drug Des; 2012 Jun; 8(2):135-58. PubMed ID: 22497469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Descriptors and their selection methods in QSAR analysis: paradigm for drug design.
    Danishuddin ; Khan AU
    Drug Discov Today; 2016 Aug; 21(8):1291-302. PubMed ID: 27326911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand-based drug design methodologies in drug discovery process: an overview.
    Bacilieri M; Moro S
    Curr Drug Discov Technol; 2006 Sep; 3(3):155-65. PubMed ID: 17311561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-dimensional QSAR in drug discovery.
    Lill MA
    Drug Discov Today; 2007 Dec; 12(23-24):1013-7. PubMed ID: 18061879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel QSAR model of Salmonella mutagenicity and its application in the safety assessment of drug impurities.
    Valencia A; Prous J; Mora O; Sadrieh N; Valerio LG
    Toxicol Appl Pharmacol; 2013 Dec; 273(3):427-34. PubMed ID: 24090816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinguishing between natural products and synthetic molecules by descriptor Shannon entropy analysis and binary QSAR calculations.
    Stahura FL; Godden JW; Xue L; Bajorath J
    J Chem Inf Comput Sci; 2000; 40(5):1245-52. PubMed ID: 11045820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.